Here’s Why Arcellx (ACLX) Declined in Q1

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Arcellx, Inc. (NASDAQ:ACLX). Headquartered in Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The one-month return of Arcellx, Inc. (NASDAQ:ACLX) was -4.56%, and its shares gained 15.63% of their value over the last 52 weeks. On May 9, 2025, Arcellx, Inc. (NASDAQ:ACLX) stock closed at $57.55 per share with a market capitalization of $3.17 billion.

Baron Health Care Fund stated the following regarding Arcellx, Inc. (NASDAQ:ACLX) in its Q1 2025 investor letter:

“Arcellx, Inc. (NASDAQ:ACLX) is developing cell therapies for multiple myeloma, including lead drug anito-cel in partnership with Gilead. Shares detracted from performance. The stock had run up as investors anticipated positive news ahead of results released in early December from a pivotal iMMagine-1 trial. Despite encouraging data showing that anito-cel is as efficacious as Legend/ Johnson & Johnson’s CARVYKTI with fewer side effects, shares then fell on fears of any new safety signals as Arcellx conducts additional trials. We think anito-cel is meaningfully differentiated on safety, and new data readouts will support this conclusion. We expect a mid-year update on trial results, which could be the basis for potential approval and launch in the second half of 2026.”

Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying

A scientist in a lab coat examining a microscope, looking at the details of the biotechnology company’s immunotherapies.

Arcellx, Inc. (NASDAQ:ACLX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Arcellx, Inc. (NASDAQ:ACLX) at the end of the fourth quarter which was 32 in the previous quarter. While we acknowledge the potential of Arcellx, Inc. (NASDAQ:ACLX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we covered Arcellx, Inc. (NASDAQ:ACLX) and shared takeover rumors that have prompted hedge funds to buy stocks. Baron healthcare fund initiated a position in Arcellx, Inc. (NASDAQ:ACLX) during Q2 2023, focusing on cell therapy’s potential for multiple myeloma care. In Q1 2024, the fund increased its stake, but Arcellx, Inc. (NASDAQ:ACLX) dropped in Q2 2024 due to lack of news and competitor programs. However, Arcellx, Inc. (NASDAQ:ACLX) surged in Q3 2024, as its iMMagine-1 trial data for late-line multiple myeloma was confirmed for presentation at the American Society for Hematology conference later this year. In Q4 2024, the fund again increased its stake in Arcellx, Inc. (NASDAQ:ACLX), driven by its accelerated growth trajectory. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.